Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2000 and based in Toronto, Canada, Genesys Capital is a life sciences venture capital firm with a fund size of $400 million. The firm has raised over $400 million across five venture funds and currently manages a portfolio of 44 companies. Their focus is on early-stage life sciences companies, collaborating with scientific founders and entrepreneurs.
Notable companies in Genesys Capital's portfolio include Fusion Pharmaceuticals Inc., acquired by AstraZeneca for $2.4 billion, and Inversago Pharma, acquired by Novo Nordisk for $1.1 billion. Other significant investments include Profound Medical Inc., which focuses on MRI-guided ultrasound devices, and Adapsyn Bioscience Inc., a biotechnology firm utilizing AI and genomic data for drug development.
To pitch Genesys Capital, submit your proposal through their form at genesyscapital.com or email your deck to info@genesyscapital.com.
Does Genesys Capital lead rounds?
Yes, Genesys Capital often leads investment rounds in the companies they back, particularly in early-stage funding.
What is Genesys Capital's stance on follow-on investments?
The firm actively participates in follow-on investments to support portfolio companies as they grow and reach subsequent funding stages.
How large is Genesys Capital's current fund?
Genesys Capital has raised over $400 million across five venture funds, focusing on early-stage life sciences investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.